8-K: Johnson & Johnson Completes Public Offering of \$4 Billion in Notes

Sentiment:

Debt Offering Completion Announcement 26 February 2025 4:23 PM

Johnson & Johnson successfully completed a public offering of \$4 billion in notes with maturities ranging from 2029 to 2055.

Capital raiseJohnson & Johnson completed a public offering of \$4 billion in notes.The offering included notes with maturities in 2029, 2033, 2037, 2045, and 2055.The company entered into an underwriting agreement with several underwriters to facilitate the offering.

Summary

Johnson & Johnson completed a public offering of notes on February 26, 2025.
The offering included \$600 million of 2.700% Notes due 2029, \$700 million of 3.050% Notes due 2033, \$1 billion of 3.350% Notes due 2037, \$700 million of 3.600% Notes due 2045, and \$1 billion of 3.700% Notes due 2055.
The notes were issued under the company's registration statement on Form S-3, Reg. No. 333-269836.
An underwriting agreement was entered into on February 19, 2025, with Citigroup Global Markets Limited, Deutsche Bank AG, London Branch, Goldman Sachs & Co. LLC, and other underwriters.

Sentiment

Score: 7

Explanation: The document is a standard announcement of a completed debt offering, which is generally viewed as a positive event for the company as it provides access to capital. The sentiment is neutral to slightly positive.

Positives

Johnson & Johnson successfully raised \$4 billion through a public offering of notes.
The offering diversifies the company's debt maturity profile with notes maturing between 2029 and 2055.
The underwriting agreement includes standard provisions and protections for both the issuer and the underwriters.

Risks

The underwriting agreement includes provisions for termination if certain adverse events occur, such as a suspension of trading on the New York Stock Exchange or a material outbreak of hostilities.
The notes are subject to optional redemption by the company, which could impact investor returns.
The notes are subject to market risks and fluctuations in interest rates.

Future Outlook

The proceeds from the notes offering may be used for general corporate purposes, including refinancing existing debt, funding acquisitions, and investing in research and development.

Industry Context

This offering reflects Johnson & Johnson's ongoing strategy to manage its debt portfolio and take advantage of favorable market conditions.

Comparison to Industry Standards

Johnson & Johnson's bond offerings are typically viewed favorably by the market due to the company's strong credit rating and stable financial performance.
Comparable companies such as Pfizer, Merck, and AbbVie also issue bonds to fund their operations and strategic initiatives.
The interest rates on Johnson & Johnson's notes are in line with industry standards for companies with similar credit ratings and maturities.

Stakeholder Impact

Shareholders: The offering could impact earnings per share depending on the use of proceeds.
Employees: The offering provides financial flexibility for the company, which could support job security and future investments.
Creditors: The offering increases the company's debt, which could impact credit ratings and borrowing costs.
Customers: The offering provides financial resources for the company to continue investing in research and development and providing innovative products.

Next Steps

The company will use the proceeds from the offering for general corporate purposes.
The notes will be listed on the New York Stock Exchange.
Interest payments will be made annually on February 26, beginning in 2026.

Key Dates

Date	Description
September 15, 1987	Date of the Indenture between Johnson & Johnson and The Bank of New York Mellon Trust Company, N.A.
September 1, 1990	Date of the First Supplemental Indenture.
February 16, 2023	Effective date of the Registration Statement on Form S-3 (File No. 333-269836).
October 31, 2022	Board of Directors of Johnson & Johnson authorization date.
February 14, 2023	Board of Directors of Johnson & Johnson authorization date.
November 9, 2017	Date of the Second Supplemental Indenture.
April 25, 2024	Board of Directors of Johnson & Johnson authorization date.
February 18, 2025	Date of the Johnson & Johnson Underwriting Agreement Standard Provisions (Debt).
February 19, 2025	Date of the Underwriting Agreement among Johnson & Johnson and the underwriters.
February 19, 2025	Pricing Term Sheet Date
February 26, 2025	Date of report (Date of earliest event reported) and completion of the public offering of the notes.
February 26, 2026	Beginning of annual interest payments for all notes.
January 26, 2029	Par call date for 2.700% Notes due 2029.
February 26, 2029	Maturity date for the 2.700% Notes.
November 26, 2032	Par call date for 3.050% Notes due 2033.
February 26, 2033	Maturity date for the 3.050% Notes.
November 26, 2036	Par call date for 3.350% Notes due 2037.
February 26, 2037	Maturity date for the 3.350% Notes.
November 26, 2044	Par call date for 3.600% Notes due 2045.
February 26, 2045	Maturity date for the 3.600% Notes.
August 26, 2054	Par call date for 3.700% Notes due 2055.
February 26, 2055	Maturity date for the 3.700% Notes.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.